Charcot-Marie-Tooth disease type 1A: is ascorbic acid effective?

The Lancet Neurology

Volumn 8, Issue 12, 2009, Pages 1075-1077

  Pareyson, Davide ^a   Solari, Alessandra ^b  

^a Department of Clinical Neurosciences   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; PERIPHERAL MYELIN PROTEIN 22;

CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; ELECTROPHYSIOLOGY; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; LETTER; MEDIAN NERVE; MOTOR NERVE CONDUCTION; PRIORITY JOURNAL; QUALITY OF LIFE; SKIN BIOPSY; WALKING;

ANTIOXIDANTS; ASCORBIC ACID; CHARCOT-MARIE-TOOTH DISEASE; CHILD; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 72149091751     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70270-4     Document Type: Letter

References (12)

1. Pareyson D., and Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol 8 (2009) 654-667
2. Passage E., Norreel J.C., Noack-Fraissignes P., et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 10 (2004) 396-401
3. Micallef J., Attarian S., Dubourg O., et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2009) 10.1016/S1474-4422(09)70260-1 published online Oct 8.
4. Shy M.E., Blake J., Krajewski K., et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 64 (2005) 1209-1214
5. Burns J., Ouvrier R.A., Yiu E.M., et al. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 8 (2009) 537-544
6. Toth C. Poor tolerability of high dose ascorbic acid in a population of genetically confirmed adult Charcot-Marie-Tooth 1A patients. Acta Neurol Scand 120 (2009) 134-138
7. Verhamme C., de Haan R.J., Vermeulen M., Baas F., de Visser M., and van Schaik I.N. Oral high dose ascorbic acid treatment for one year did not improve myelination in young CMT1A patients: a proof of principle pilot study. J Periph Nerv Syst 14 suppl (2009) 152-153
8. Shy M.E., Chen L., Swan E.R., et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 70 (2008) 378-383
9. Reilly M.M., de Jonghe P., and Pareyson D. 136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A). 8-10 April 2005, Naarden, the Netherlands. Neuromuscul Disord 16 (2006) 396-402
10. Solari A., Laurà M., Salsano E., Radice D., Pareyson D., and for the CMT-TRIAAL study group. Reliability of clinical outcome measures in Charcot-Marie-Tooth disease. Neuromuscul Disord 18 (2008) 19-26
11. Pareyson D., Schenone A., Fabrizi G.M., et al., for the CMT-TRIAAL Group. A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27]. Pharmacol Res 54 (2006) 436-441
12. Chalmers I., Hedges L.V., and Cooper H. A brief history of research synthesis. Eval Health Prof 25 (2002) 12-37